On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor antibody screen on the Ortho Clinical Diagnostics VISION Analyzer. This instrumentation change was necessary as Ortho Clinical Diagnostics will be discontinuing support of the existing ProVue instrumentation in the future.
We will notify you of the transition date of our other four laboratories. To read more about this change, click here: Communications
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...